|
|
Article: Novirio Looks To Go Public, Files For Estimated $115M IPO.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Novirio Pharmaceuticals Ltd. filed for its initial public offering, seeking $115 million and proposing the ticker symbol IDIX.
Cambridge, Mass.-based Novirio is developing antiviral therapies for hepatitis and HIV infection. It focuses on nucleoside chemistry and biology. The company was founded in 1998 and has raised more than $69 million from U.S., European and Asian investors, including a $44 million Series C round in May 2001. (See BioWorld Today, May 8, 2001.)
The offering is being co-led by Goldman Sachs & Co., of New York, and Banc of America Securities LLC, of San Francisco. Also participating are JP Morgan Securities ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cel-Sci Acquisition Inc., of the British Virgin Islands, ...
BIOWORLD Today;
August 23, 1999 ;
700+ words
... ... Corp.'s legal counsel. (See BioWorld Today, Aug. 20, 1999, p. 1 ... Bristol-Myers Squibb Co., of New York, as part of its license and ... 87 million in cash. (See BioWorld Today, Aug. 3, 1999, p. 1 ...
|
|